LYSINE ASPARTATE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C6H14N2O2.C4H7NO4
Molecular Weight	279.2902
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

N[C@@H](CC(O)=O)C(O)=O.NCCCC[C@H](N)C(O)=O

InChI

InChIKey=CPYVQXAASIFAMD-KNIFDHDWSA-N

InChI=1S/C6H14N2O2.C4H7NO4/c7-4-2-1-3-5(8)6(9)10;5-2(4(8)9)1-3(6)7/h5H,1-4,7-8H2,(H,9,10);2H,1,5H2,(H,6,7)(H,8,9)/t5-;2-/m00/s1

HIDE SMILES / InChI

Molecular Formula	C4H7NO4
Molecular Weight	133.1027
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C6H14N2O2
Molecular Weight	146.1876
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.nap.edu/read/10490/chapter/12
Curator's Comment: description was created based on several sources, including https://www.drugs.com/npp/lysine.html | https://www.ncbi.nlm.nih.gov/pubmed/26252373

Lysing is an essential basic amino-acid encoded by codone AAA and AAG, and used in the biosynthesis of proteins. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken. In a clinical study lysine supplements was found to be an effective for reduction of occurrence, severity and healing time for recurrent HSV infection, however Cochrane Review concluded that the evidence is insufficient. Lysine was investigated for improving anxiety, ameliorating angina prectoris. Lysine acetylsalicylate has been used to treat pain and to detoxify the body after heroin use. Lysine clonixinate has been used for its analgesic properties for the treatment of migraine headaches and other painful conditions. However, limited clinical trials exist for these conditions.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 4 (5-HT4) receptor 38 Target ID: CHEMBL1875 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28103616	Antagonist 2849
GABA-A receptor; anion channel 203 Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8587651	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Herpes simplex infection 28 Sources: https://www.drugs.com/npp/lysine.html	Primary	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine has been studied for the prevention and treatment of herpes infections and cold sores.
Angina pectoris 110 Sources: https://www.drugs.com/npp/lysine.html	Primary	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine supplements may relieve effort-related angina pectoris.
Osteoporosis 101 Sources: https://www.drugs.com/npp/lysine.html	Primary	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine increases the intestinal absorption and reduces the renal elimination of calcium.
Anxiety 275 Sources: https://www.drugs.com/npp/lysine.html	Primary	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine is believed to exert anxiolytic effects by acting as a partial serotonin receptor 4 antagonist and as a partial benzodiazepine agonist
Heroin dependence 10 Sources: https://www.drugs.com/npp/lysine.html	Palliative	Natural Metabolite	L-LYSINE MONOHYDRATE Approved Use Lysine acetylsalicylate has been used to detoxify the body after heroin use.
Patent ductus arteriosus 8 Sources: https://www.drugs.com/pro/neoprofen.html	Primary	Approved 8583	NEOPROFEN Approved Use NeoProfen is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. Launch Date 2006

PubMed

Title	Date	PubMed
Antibodies to SOX13 (ICA12) are associated with type 1 diabetes.	2001	11264788
Protein profiling comes of age.	2001	11182890
Thermal and enzymatic recovering of proteins from untanned leather waste.	2001	11150136
Glycophorin as a receptor for Escherichia coli alpha-hemolysin in erythrocytes.	2001 Apr 20	11134007
The effect of protease inhibitors on the two-dimensional electrophoresis pattern of red blood cell membranes.	2001 Feb	11258769
In vivo distribution and speciation of [114mIn]InCl3 in the Wistar rat.	2001 Feb	11253025
How does endotoxin trigger inflammation in otitis media with effusion?	2001 Feb	11210878
Combination of HPLC and solid-phase binding assay for isolation and purification of MHC class I and associated peptides using a bladder tumour cell line.	2001 Feb	11180296
Affinity purification of Csk protein tyrosine kinase based on its catalytic requirement for divalent metal cations.	2001 Feb	11162381
Increased L-arginine uptake and inducible nitric oxide synthase activity in aortas of rats with heart failure.	2001 Feb	11158987
The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis.	2001 Feb	11156641
Evidence that fragile X mental retardation protein is a negative regulator of translation.	2001 Feb 15	11157796
Identification of novel hypocholesterolemic peptides derived from bovine milk beta-lactoglobulin.	2001 Feb 16	11178953
Identification of a candidate integrin-fraction associated with the activated form of the PDGF-receptor.	2001 Feb 23	11181089
Uptake and accumulation of exogenous docosahexaenoic acid by Chlorella.	2001 Jan	11272831
Endotoxemia and acute-phase proteins in major abdominal surgery.	2001 Jan	11248174
A novel protein-RNA binding assay: functional interactions of the foot-and-mouth disease virus internal ribosome entry site with cellular proteins.	2001 Jan	11214173
Granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods.	2001 Jan	11207017
Charge-dependent binding of polymeric IgA1 to human mesangial cells in IgA nephropathy.	2001 Jan	11135081
Selectively labeling the heterologous protein in Escherichia coli for NMR studies: a strategy to speed up NMR spectroscopy.	2001 Jan	11133287
Increased stability of nucleophosmin/B23 in anti-apoptotic effect of ras during serum deprivation.	2001 Jan	11125022
A Mycobacterium smegmatis gyrase B specific monoclonal antibody reveals association of gyrase A and B subunits in the cell.	2001 Jan 1	11150671
Cryptosporidium infection in Bedouin infants assessed by prospective evaluation of anticryptosporidial antibodies and stool examination.	2001 Jan 15	11159166
RNA interference is mediated by 21- and 22-nucleotide RNAs.	2001 Jan 15	11157775
Identification of lysine 346 as a functionally important residue for pyridoxal 5'-phosphate binding and catalysis in lysine 2, 3-aminomutase from Bacillus subtilis.	2001 Jan 16	11148055
A single-chain variable region immunoglobulin library from the abomasal lymph node of sheep infected with the gastrointestinal nematode parasite Haemonchus contortus.	2001 Jan 26	11182152
Bullous pemphigoid: interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation.	2001 Jan 7	11145840
Purification of recombinant green fluorescent protein using chromatofocusing with a pH gradient composed of multiple stepwise fronts.	2001 Jan-Feb	11170493
Chemical and biological evaluation of endotoxin contamination on natural rubber latex products.	2001 Jun 5	11255197
Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA.	2001 Mar	11235953
Mechanisms of photoreceptor cell death in cancer-associated retinopathy.	2001 Mar	11222531
Post-transcriptional effects of extracellular pH on tumour necrosis factor-alpha production in RAW 246.7 and J774 A.1 cells.	2001 Mar	11222111
Quantitative analysis of specific mRNA species in minute cell samples by RT-PCR and flow cytometry.	2001 Mar 1	11226479
Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.	2001 Mar 15	11275975
Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.	2001 Mar 21	11257391
Western blotting as a method for studying cell-biomaterial interactions: the role of protein collection.	2001 Mar 5	11189044
Isolation and characterization of senescence-induced cDNAs encoding deoxyhypusine synthase and eucaryotic translation initiation factor 5A from tomato.	2001 May 18	11278418

Patents

Sample Use Guides

In Vivo Use Guide

Lysin is an essential amino-acid. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken.

Route of Administration: Oral

In Vitro Use Guide

In the in vitro study of herpes simplex virus (HSV) growth in tissue culture, arginine deficiency suppressed HSV growth. Maximum herpes growth (as measured by plaques counting) was observed in flasks, containing 10-20 ug/ml of arginine. The addition of 50 ug/ml of lysine to the flasks containing 2.5 and 5.0 ug/ml of arginine reduced the number of viable plaque-forming units (PFU) from 3300 and 48800 to less than 10.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:52:27 GMT 2025` Edited by `admin` on `Mon Mar 31 17:52:27 GMT 2025`
Record UNII	23227F83U0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LYSINE ASPARTATE

Official Name

English

L-ASPARTIC ACID, COMPD. WITH L-LYSINE (1:1)

Preferred Name

English

L-LYSINE, L-ASPARTATE (1:1)

Common Name

English

L-LYSINE-L-ASPARTATE

Common Name

English

LYSINE L-ASPARTATE, L-

Common Name

English

LYSINE, L-, L-ASPARTATE (1:1)

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID80181785